@article{14ca56dacf4a4a68979c98a777e702ee,
title = "Erratum: Gene therapy for neurological disorders: Progress and prospects (Nature reviews drug discovery, (2018) 19, (641-669), 10.1038/nrd.2018.158)",
abstract = "Details related to the copyright permissions for the images shown in Figure 3 have been added to the figure legend.",
author = "Deverman, {Benjamin E.} and Ravina, {Bernard M.} and Bankiewicz, {Krystof S.} and Paul, {Steven M.} and Sah, {Dinah W.Y.}",
note = "Funding Information: The authors thank their colleagues at Voyager Therapeutics for numerous discussions on adeno-associated viral (AAV) gene therapy for central nervous system (CNS) disorders and the Parkinson disease team and P. Larson for their work on the delivery of AAV2–aromatic-l-amino-acid decarboxylase (AADC) gene therapy in patients with Parkinson disease with intraparenchymal brain administration. The authors also thank E. Smith, W. Yen and M. Lawrence for assistance with the figures, tables and text, respectively. B.E.D. was supported by the Beckman Institute for the CLARITY, Optogenetics and Vector Engineering Research Center (CLOVER) at the California Institute of Technology, the Friedreich{\textquoteright}s Ataxia Research Alliance (FARA) and FARA Australasia and the CHDI Foundation and is currently supported by the Stanley Center for Psychiatric Research at Broad Institute. K.S.B. was supported by the Michael J. Fox Foundation. B.M.R., S.M.P. and D.W.Y.S. are currently employees of Voyager Therapeutics, a CNS gene therapy company working on AAV vectors for the treatment of severe neurological diseases. Publisher Copyright: {\textcopyright} 2018 Springer Nature Limited. All rights reserved.",
year = "2018",
month = oct,
day = "1",
doi = "10.1038/nrd.2018.110",
language = "English",
volume = "17",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
number = "10",
}